KLRS Kalaris Therapeutics, Inc. Insider Trading

Director Srinivas Akkaraju buys 244,300 KLRS shares at $4.83 ($1.2M); stock down 58.6% from 52-week high, -22.3% in 30 days.

Srinivas Akkaraju, a Director at unprofitable Kalaris Therapeutics (full-year net income: $-10,856,000.00), purchased 244,300 shares at $4.83 on 2026-05-20, bringing his holding to 19,408 shares post-transaction. The purchase represents a notable dollar commitment ($1,179,969.00) into a stock trading at $4.92 currently, down 58.6% from its 52-week high of $11.88 and off 50.8% over the past 90 days. His cross-ticker track record shows strong timing (20 prior buys averaging +197.1% 90-day returns with a 95.00% win rate), yet his single prior buy at KLRS (2025-12-18) produced a -27.7% 90-day return, indicating this ticker has not aligned with his typical execution pattern. The company's unprofitable status and continued downward price momentum provide limited fundamental support for the accumulation.

Director Akkaraju Srinivas bought 479,847 shares of KLRS at $10.42 ($5.0M), raising holdings by 32.0% as stock trades 28.0% below 52-week high.

Akkaraju Srinivas, a Director, deployed $5,000,005.74 to purchase 479,847 shares at $10.42, increasing his stake from 1,500,000 shares to 1,979,847 shares. This represents a 32.0% increase in his holdings. The purchase was made when the stock trades at $8.26, which is 28.0% below its 52-week high of $11.47 and 15.2% down over the past 30 days, suggesting the insider acquired shares following recent weakness. Notably, Srinivas's cross-ticker track record shows 20 prior open-market buys with an average 90-day return of +129.8% and a 100.00% win rate, though the company itself is unprofitable with net income of $-11,894,000.00 over its most recent full fiscal year. The large dollar commitment and aggressive holding expansion by an insider with a strong historical track record at capital deployment warrant investor attention, particularly given the depressed relative price at which the purchase occurred.